| h-ed41a306c5 | VDAC1 Hyper-Oligomerization via Direct TDP-43 Binding | 0.50 | 0.45 | VDAC1, VDAC2 | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062141-739c7f1c |
| h-var-80a3b3dd52 | Temporal NLRP3 Inhibition via SPP1-Mediated Mitophagy Enhancement During Critica | 0.50 | 0.39 | NLRP3 | promoted | 2026-04-21 | SDA-2026-04-15-gap-pubmed-20260406-062118-e3613755 |
| h-var-f19f044a9a | TREM2-Mediated Microglial Metabolic Reprogramming Accelerates Tau Pathological S | 0.49 | 0.67 | TREM2 | proposed | 2026-04-21 | SDA-2026-04-03-26abc5e5f9f2 |
| h-b97e6bb5f1 | Lamin B1 Degradation as Irreversibility Gate | 0.49 | 0.52 | LMNB1, LMNB2, NCOA4, SQSTM1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062101-724971bc |
| h-f11788656b | YAP/TAZ Mechanosensing Cooperates with NF-κB to Amplify SPP1 Transcription in Pe | 0.49 | 0.42 | SPP1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-5e49e14f |
| h-var-bee1a6239c | GluN2B-Regulated Microglial Phagocytosis of Tau Aggregates via CX3CR1 Signaling | 0.49 | 0.67 | GRIN2B | proposed | 2026-04-21 | SDA-2026-04-03-26abc5e5f9f2 |
| h-ed53359485 | Astrocyte GAT-3 dysfunction and inhibitory-network disruption in ALS/FTD | 0.49 | 0.46 | SLC6A13; SLC12A5; SLC12A2 | proposed | 2026-04-30 | SDA-2026-04-30-gap-test-20260425-224949 |
| h-6b489d1dee | Autophagy Enhancement via mTOR Inhibition for C9orf72 Dipeptide Repeat Pathology | 0.49 | 0.55 | MTOR/C9orf72 | proposed | 2026-04-28 | SDA-2026-04-28-gap-test-20260425-224949 |
| h-f9e4985929 | Tumor-derived extracellular vesicles as TREM2 ligands | 0.49 | 0.45 | TREM2 ligands on tumor EVs | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-150544-e3a2eab9-debate |
| h-a0bd8d4f4c | Reactive astrocyte glutamate-handling failure sustains dendritic tau-associated | 0.49 | 0.47 | SLC1A2,GRIN2B,MAPT | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-98a600b3ed |
| h-588406cca9 | G3BP1-TDP-43 Cross-Seeding Drives Co-Aggregation That Prion-Spreads Across Neura | 0.49 | 0.52 | TARDBP | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041428-e14e6524 |
| h-6be018d35a | Testosterone-Derived DHT Amplifies Microglial Androgen Receptor Signaling Drivin | 0.49 | 0.52 | AR | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041439-ec89b1e4 |
| h-373fac84b5 | P2RY12/P2RY13 Purinergic Receptor Metabolic Rewiring | 0.49 | 0.48 | P2RY12, P2RY13, CTNNB1 (β-catenin), GSK3β | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755 |
| h-c40be3e018 | OPA1-Mediated Cristae Architecture Vulnerability | 0.49 | 0.48 | OPA1, MFN1/2, DRP1 (DNM1L), mitochondrial protease cleavage | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046 |
| h-23cba4e15d | Targeting AQP4 Sumoylation to Enhance Glymphatic Clearance as Therapeutic Strate | 0.49 | 0.44 | AQP4; SENP1; SENP2; UBC9 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e |
| h-45b0992fc4 | Mitochondrial Proteostasis Hijacking | 0.49 | 0.52 | TOMM40 | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a |
| h-6f6f920e83 | Sulfated glycans and metal-binding CSF proteins brace alpha-synuclein fibril pol | 0.49 | 0.42 | SNCA | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260411-081644-1d2624b8-debate |
| h-a976bf02b0 | Structured Intronic Scaffold Regions in Enhancer-dilncRNAs Enable Cell-Type Sele | 0.49 | 0.42 | ECEPs (PAX6-AS1, KCNC2-AS1) | proposed | 2026-04-21 | SDA-2026-04-10-gap-debate-20260410-075007-232fbf62 |
| h-var-3993e74fb3 | C1q-Mediated Delivery of miR-33 Antisense Oligonucleotides for Enhanced APOE4 Li | 0.49 | 0.36 | miR-33a/miR-33b | promoted | 2026-04-20 | SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e |
| h-var-8c9cecfc00 | SREBP-2 Direct Inhibition Hyper-Lipidation Strategy | 0.49 | 0.36 | SREBF2/ABCA1 | promoted | 2026-04-20 | SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e |
| h-4b91b4b2d5 | Hyperphosphorylated TDP-43 Traps TRIM21 Into Inactive Complexes | 0.49 | 0.48 | TARDBP, TRIM21 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041423-3a6aa4ab |
| h-92a69aa3 | USP14 Inhibition to Accelerate Proteasomal Degradation of Synaptic Substrates | 0.49 | 0.46 | USP14 (ubiquitin-specific peptidase 14) | proposed | 2026-04-25 | SDA-2026-04-16-frontier-proteomics-1c3dba72 |
| h-3a0c21057e | Kinesin-Dependent Peripheral Microtubule Transport Maintains Receptor Exclusion | 0.49 | 0.42 | KIF5B/KIF5C | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-041423-9c2c2ee3 |
| h-var-73142bada1 | APOE4 Structural Remodeling via HSP70 Chaperone Enhancement Strategy | 0.49 | 0.37 | HSP70/APOE4 | promoted | 2026-04-21 | SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e |
| h-2a1a95c1 | Oligodendrocyte Progenitor Cell Metabolic Reprogramming | 0.49 | 0.40 | PDK1, PFKFB3, LDHA | archived | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222543-20260402 |
| h-SDA-2026-04-26-gap | Soluble LRP1 Fragments Serve as Blood-Based Indicators of Impaired Aβ Efflux and | 0.49 | 0.30 | LRP1 | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260426-001521 |
| h-SDA-2026-04-26-gap | Plasma NfL Elevation Secondary to BBB-Associated Transport Dysfunction Enables L | 0.49 | 0.30 | NEFL | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260426-001521 |
| h-a3f785df | Sonic hedgehog pathway compartmentalization as quantitative biomarker for neuron | 0.49 | 0.45 | ADCY3 (adenylate cyclase), ARL13B (ciliary targeting), GNAI1 | proposed | 2026-04-26 | SDA-2026-04-10-gap-debate-20260410-075000-7396040a |
| h-var-71a27b2aa2 | TFEB-Mediated Lysosomal Biogenesis Enhancement for NLRP3 Inflammasome Regulation | 0.48 | 0.40 | TFEB | promoted | 2026-04-21 | SDA-2026-04-03-gap-immune-atlas-neuroinflam-20260402 |
| h-var-fe9c7bfb0c | GluN2B-Mediated Perivascular Pericyte Control of Glymphatic Tau Clearance | 0.48 | 0.67 | GRIN2B | proposed | 2026-04-21 | SDA-2026-04-03-26abc5e5f9f2 |
| h-var-45ec9caaa4 | PINK1/PARK2-LC3 Mitophagy Enhancement | 0.48 | 0.40 | PINK1 | promoted | 2026-04-21 | SDA-2026-04-03-gap-immune-atlas-neuroinflam-20260402 |
| h-f86127b5 | HDAC6 Inhibition for Dual Restoration of Microtubule Stability and Autophagic Ta | 0.48 | 0.52 | HDAC6 | proposed | 2026-04-13 | SDA-2026-04-13-gap-debate-20260412-094612-a2e3bd09 |
| h-var-c0ea5a3d50 | Distinct J-protein architectures decode exposed β-sheet recognition codes to ena | 0.48 | 0.35 | DNAJB6 | proposed | 2026-04-26 | SDA-2026-04-10-gap-debate-20260410-075012-32bac138 |
| h-var-c60fc47c34 | Parthenolide enhances ADORA2A receptor internalization through direct sesquiterp | 0.48 | 0.40 | ADORA2A | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-193037-1dc5e03a-debate |
| h-43a8ab92dd | SIRT3 gates microglial surveillance versus primed metabolism through mitochondri | 0.48 | 0.38 | SIRT3 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062033-839c3e2a |
| h-d78123d1 | Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial D | 0.48 | 0.30 | RAB27A/LAMP2B | archived | 2026-04-02 | SDA-2026-04-01-gap-20260401231108 |
| h-fa079a4295 | Isoform-Selective Hsp70 Targeting Overcomes Stoichiometric Imbalance in Advanced | 0.48 | 0.55 | HSPA1A, DNAJB6, DNAJB8 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062052-28cbc764 |
| hyp-sda-2026-04-01-0 | FCER1G-Mediated Alternative Immune Signaling | 0.48 | 0.50 | ['FCER1G'] | active | 2026-04-27 | sda-2026-04-01-001 |
| hyp-sda-2026-04-01-0 | Soluble TREM2 Sequestration and Recycling | 0.48 | 0.50 | ['TREM2'] | active | 2026-04-27 | sda-2026-04-01-001 |
| hyp-sda-2026-04-01-0 | SIRPA-Mediated Microglial Disinhibition | 0.48 | 0.50 | ['SIRPA'] | active | 2026-04-27 | sda-2026-04-01-001 |
| hyp-sda-2026-04-01-0 | TYROBP-SYK Pathway Enhancement | 0.48 | 0.50 | ['TYROBP', 'SYK'] | active | 2026-04-27 | sda-2026-04-01-001 |
| hyp-sda-2026-04-01-0 | Temporal TREM2 Pathway Modulation | 0.48 | 0.50 | ['TREM2', 'TYROBP'] | active | 2026-04-27 | sda-2026-04-01-001 |
| hyp-sda-2026-04-01-0 | Multi-Target Microglial Metabolic Reprogramming | 0.48 | 0.50 | ['TREM2', 'APOE', 'CLU'] | active | 2026-04-27 | sda-2026-04-01-001 |
| hyp-sda-2026-04-01-0 | APOE-TREM2 Synergistic Modulation | 0.48 | 0.50 | ['APOE', 'TREM2'] | active | 2026-04-27 | sda-2026-04-01-001 |
| h-b7c58d63d6 | Brain Insulin Resistance and Metabolic Dysregulation | 0.48 | 0.52 | IRS1, INSR, IGF1R, AKT | proposed | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-7856aa8a | SIRT1 Activator Therapy for Mitochondrial Epigenetic Dysregulation | 0.48 | 0.52 | SIRT1 pathway / NAD+ metabolism | proposed | 2026-04-25 | SDA-2026-04-16-gap-epigenetic-adpdals |
| h-00073ccb | DNA Methylation Clock Drift at Glial Promoters | 0.48 | 0.55 | DNA Methylation Clock | proposed | 2026-04-25 | SDA-2026-04-19-gap-epigenetic-comparative-ad-pd-als |
| h-e91a4dd06a | FSP1/CoQ10 Axis as GPX4-Independent Neuroprotective Pathway | 0.48 | 0.55 | FSP1 (NQO1/FDXR axis) / CoQ10 biosynthetic pathway | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-174000-6451afef-debate |
| h-2b95e7ad70 | Extracellular Vesicle Cargo Transfer | 0.48 | 0.40 | GW4869 target; EV biogenesis genes | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-170057-a2f72fd8-debate |
| h-dcd272ed1f | TH-neuron-restricted RGS6 rescue to test cell-autonomous therapeutic sufficiency | 0.48 | 0.36 | RGS6 | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-145520-5692b02e-debate |